JNJJanssen Research & Development, LLCSigning up patients
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Metastatic Prostate Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 1/2
- Patients
- 190 (planned)
- Started
- Feb 6, 2025
- Main results expected
- Aug 17, 2028
- Fully finished
- Aug 17, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Frequency of dose-limiting toxicities (DLTs)
Measured over: 21 days
Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baseline
Measured over: 21 days
Phase 1 Part 2 (formulation exploration) relative bioavailability
Measured over: 22 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06800313 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC